Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial
✍ Scribed by Philip Mease; Mark C. Genovese; Geoffrey Gladstein; Alan J. Kivitz; Christopher Ritchlin; Paul P. Tak; Jürgen Wollenhaupt; Orna Bahary; Jean-Claude Becker; Sheila Kelly; Leonard Sigal; Julie Teng; Dafna Gladman
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 215 KB
- Volume
- 63
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract ## Objective To determine the clinical efficacy, safety, and immunogenicity of abatacept (CTLA‐4Ig), a selective costimulation modulator, in patients with rheumatoid arthritis (RA) that has remained active despite methotrexate (MTX) therapy. ## Methods This was a 12‐month, multicente
## Abstract ## Objective There is increasing evidence that tumor necrosis factor α (TNFα) is centrally involved in the pathogenesis of ankylosing spondylitis (AS) and other spondylarthritides. This study was designed to investigate the efficacy of anti‐TNFα therapy with etanercept, a 75‐kd recepto
## Abstract ## Objective To assess the efficacy and safety of gabapentin in patients with fibromyalgia. ## Methods A 12‐week, randomized, double‐blind study was designed to compare gabapentin (1,200–2,400 mg/day) (n = 75 patients) with placebo (n = 75 patients) for efficacy and safety in treatin
## Abstract ## Objective To evaluate the efficacy and safety of alefacept in combination with methotrexate (MTX) for the treatment of psoriatic arthritis (PsA). ## Methods Patients were eligible for this randomized, double‐blind, placebo‐controlled trial if they were ages 18–70 years and had act